Eli Lilly’s stock soars as Mounjaro, Zepbound sales lead to a big profit beat

Date:

August 8, 2024

Eli Lilly’s stock was headed for its best day in a year on Thursday, after the drugmaker reported second-quarter earnings that rose well above forecasts, amid strength in sales of its diabetes and obesity treatments, Mounjaro and Zepbound.

Source link

Chime and Dave execs are coming to TechCrunch Disrupt 2024

Newsom's Mess: Fed Audit Finds Failure to Safeguard Millions of Dollars in Homelessness Funding

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Eli Lilly’s stock soars as Mounjaro, Zepbound sales lead to a big profit beat

Recent posts

Gold posts record-high finish, lifted by Fed rate-cut hopes, Middle East violence

Icahn Enterprises says class-action suit following report by short seller Hindenburg Research has been thrown out

Weight-loss drugs may reduce opioid and alcohol abuse by up to 50%, study finds

DoorDash loses more than expected in Q2. But shares are rallying, and it plans to keep investing in expansion.

Republicans say that limiting immigration will help reduce inflation. Economists aren’t so sure.

Beyond AI, AMD and Intel earnings will hit on another important trend

Super Micro needs a new CEO before its AI advantage erodes

Harley-Davidson’s stock down 2% as lowered guidance offsets earnings beat

Chamber of Commerce calls on Biden to stop dockworkers strike, citing inflation fears

Under Armour’s ‘affinity for the underdog’ helps send stock toward record gain

TSMC, Samsung reportedly consider building huge chip factories in UAE

Oil prices steady as traders monitor demand outlook, await Fed decision

Eli Lilly’s Zepbound pricing shuffle leaves some patients fearing higher costs

NASA astronauts ‘confident’ in Boeing Starliner’s ability to get them home safely

Kamala Harris backs smaller rise in capital-gains taxes than proposed by Biden

Related articles

Cocoa’s the best-performing commodity in 2024 — and even beat bitcoin. What’s next.

As the wealthy keep spending, here’s why the middle class is in for a tough 2025

How this Treasury-market dynamic could lead to the next big leg lower in stocks

As Teamsters go on strike, Amazon and its investors are trying to shrug it off

Oil may ‘collapse’ below $50 a barrel in 2025 if this perfect storm hits the market

New investigation rips Amazon’s safety record. That’s not slowing the tech giant’s stock.

U.S. oil prices drop nearly 1% on weak Chinese retail-sales data

UnitedHealth Group CEO says healthcare needs fixing. Start with these 3 problems in claims and patient costs, experts say.

Company

Follow us